Hazem Albandar, MD
Neurology · Newburgh, INNPI 1134655491
Payments from drug & device makers
Across 530 payments — averaging $84.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$22K
- Livanova USA, Inc.$15K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$738
- SK Life Science, Inc.$580
- Eisai Inc.$549
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$28,20063%
- Travel & lodging$5,14112%
- Food & beverage$10,93425%
- Education$2821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 95 | $22,443 |
| Livanova USA, Inc. | 50 | $14,953 |
| AbbVie | 127 | $1,704 |
| Teva Pharmaceuticals USA, Inc. | 35 | $738 |
| SK Life Science, Inc. | 22 | $580 |
| Eisai Inc. | 18 | $549 |
| Catalyst Pharmaceuticals, Inc. | 26 | $513 |
| Pfizer | 41 | $491 |
| Jazz Pharmaceuticals Inc. | 15 | $389 |
| Neurelis, Inc. | 19 | $347 |
| Lundbeck LLC | 19 | $327 |
| Novartis | 16 | $277 |
| Sumitomo Pharma America, Inc. | 9 | $168 |
| Ceribell, Inc. | 1 | $153 |
| AstraZeneca | 1 | $123 |
| Sanofi | 1 | $74 |
| Genentech USA, Inc. | 4 | $71 |
| Amgen | 4 | $69 |
| TG Therapeutics, Inc. | 2 | $60 |
| Bristol Myers Squibb | 3 | $59 |
| Neuropace, Inc. | 1 | $54 |
| Lilly USA, LLC | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Biogen | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Medtronic | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Aucta Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nayzilam$13,178
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$10,720
- Briviact$7,088
- VNS Therapy$3,151
- Ceribell Rapid Response EEG$153
- ULTOMIRIS$123
- XCOPRI$115
How this compares
$44,558 in reported general payments places this provider in the 80th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 88 | $128,373 |
| FycompaPerampanel | 49 | $64,558 |
| NayzilamMidazolam | 52 | $56,922 |
| AptiomEslicarbazepine Acetate | 30 | $50,541 |
| EpidiolexCannabidiol (Cbd) | 22 | $49,366 |
| UbrelvyUbrogepant | 21 | $30,316 |
| XcopriCenobamate | 29 | $28,151 |
| Emgality PenGalcanezumab-Gnlm | 32 | $27,445 |
| QuliptaAtogepant | 19 | $26,524 |
| Lacosamide | 145 | $25,952 |
| VimpatLacosamide | 13 | $16,565 |
| Levetiracetam | 555 | $16,386 |
| Clobazam | 27 | $7,914 |
| Diazepam | 15 | $5,425 |
| DilantinPhenytoin Sodium Extended | 19 | $3,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam, Vimpat | $22,443 | $201,860153 claims |
| Eisai Inc.Fycompa | $549 | $64,55849 claims |
| AbbVieUbrelvy, Qulipta | $1,704 | $56,84040 claims |
| SK Life Science, Inc.Xcopri | $580 | $28,15129 claims |
| PfizerDilantin | $491 | $3,63119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 neurology providers in Indiana.
Other neurology in Newburgh
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
- Alexandru BarboiIndianapolis$1.9M
- William ConteMerrillville$1.7M
- James StevensFort Wayne$1.5M
- Kathryn NevelIndianapolis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.